XML 60 R83.htm IDEA: XBRL DOCUMENT v2.4.0.8
Share-based Payments (Narrative) (Details) (USD $)
In Millions, except Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Sep. 29, 2013
Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized   25,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant   20,728,313
Stock Options
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Exercise price percentage of the fair market value price at date of grant   100.00%
Contractual term   10 years
Award vesting period   3 years
Restricted Stock Units (RSUs)
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares)   980,093
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 26.79
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period   2,669
Award vesting period   3 years
Deferred Stock Units (DSUs)
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Granted (in shares)   34,804
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 28.15
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period   35,024
Pfizer Stock Benefit Plans
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Contractual term   3 years 0 months 0 days
Other Equity-Based or Cash-Based Awards
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Maximum annual payment made to plan participant   $ 10
Additional expense of accelerated vesting of the outstanding Pfizer stock options, and the settlement 9  
Cash payment next quarter $ 20